Pozen, Inc.
6330 Quadrangle Drive
Suite 240
Chapel Hill
North Carolina
27514
United States
Tel: 919-490-0012
243 articles about Pozen, Inc.
-
Pozen Announces Stockholder Approval Of Its Transaction With Tribute Pharmaceuticals Canada Inc.
2/2/2016
-
Pozen to Re-File YOSPRALA NDA Early, Provides Update On Key Milestones For 2016
12/28/2015
-
Departing Pozen Execs Receive Big Pay Day as Company Looks to Merger with Tribute
12/28/2015
-
Pozen, Tribute Confirm Merger Plans to Form Aralez Pharma
12/8/2015
-
Pozen And Tribute Provide Update On Pending Combination Transactions
11/23/2015
-
Pozen Reports Third Quarter 2015 Results
11/9/2015
-
Pozen To Announce Third Quarter 2015 Results On November 9, 2015
10/26/2015
-
Pozen Reports Second Quarter 2015 Results
8/10/2015
-
Pozen Announces August 10th Webcast Of Second Quarter 2015 Results
7/27/2015
-
Pozen Announces Key Leadership Additions
6/22/2015
-
How a Reorganized Pozen Will Beef Up Sales Force and Take On the Cardiology Market
6/17/2015
-
Pozen, Inc., Tribute to Unite Under Newly Formed Aralez Label
6/8/2015
-
Pozen, Inc. Announces Strategic Acquisition Of Tribute And Growth Capital Commitment From Leading Healthcare Sponsors
6/8/2015
-
Pozen, Inc. Forms An Irish Subsidiary And Enters Into An Intangible Property Transfer Arrangement
6/2/2015
-
Pozen, Inc. Announces Retirement Of Founder, Chairman And CEO Dr. John R. Plachetka; Adrian Adams Named As CEO
6/1/2015
-
Pozen, Inc. Announces May 8th Webcast Of First Quarter 2015 Results
5/5/2015
-
Pozen, Inc. Reports Fourth Quarter And Year End 2014 Results
3/9/2015
-
Pozen, Inc. Terminates Another Deal; This Time With Johnson & Johnson
12/30/2014
-
Pozen, Inc. Crashes As FDA Rejects Two Forms Of Its Lead Drug Yosprala
12/18/2014
-
Pozen, Inc.’s YOSPRALA™ Receives Complete Response Letter From The FDA
12/17/2014